comparemela.com

Latest Breaking News On - Preclinical pharmacology - Page 1 : comparemela.com

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress - Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress - Unicycive Therapeutics (NASDAQ:UNCY)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden. Shalabh Gupta, MD, Chief Execu

Unicycive Therapeutics (UNCY) Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

Unicycive Therapeutics (UNCY) Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

NX-5948 received Fast Track designation from the FDA NX-5948 showed positive results in Phase 1 clinical trial establishing a robust foundation for advancement in CLL Licensed to Gilead a new.

The Virus Hackers

A research team from the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM and the Hannover Medical School (MHH) have made significant progress in developing a new antiviral therapy. The drug, which is inhaled, uses RNAi to target and deactivate parainfluenza viruses before they multiply.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.